Associated Press - WASHINGTON (AP) -- Federal health officials have approved an experimental drug to treat psychotic delusions and behaviors that often afflict patients with Parkinson's disease, the debilitating movement disorder.
The drug from Acadia Pharmaceuticals Inc. is the first drug for the condition, which affects approximately half of Parkinson's patients. An estimated 50,000 Americans are diagnosed with Parkinson's each year, making it the second-most common neurodegenerative disease in the U.S.
The company's drug Nuplazid is part of the antipsychotic family of medications, including Abilify, Zyprexa and Seroquel, which are used to treat schizophrenia and bipolar disorder. Like those drugs, Nuplazid will carry a boxed warning about the risks of death when used in older patients with dementia. The drugs are not approved for that use. Acadia is based in San Diego.
Copyright Associated Press
- Stop & Shop recalls frozen broccoli amid listeria concerns
- Parents and staff concerned over security protocols not followed after shooting near Holyoke school
- State Gaming Commission asking for public input on MGM's drinking hours request
- Brynn Cartelli keeping busy with interviews and events after winning The Voice
Copyright 2018 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
- Teacher and student shot at Indiana middle school; shooter in custody
- Young family forced to find new home after fissure opens in front yard
- 'He was so determined:' Bus driver who took life-changing viral pic
- Mom intentionally pulled 8-year-old son into path of train in murder-suicide, authorities say